CY1112649T1 - Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου - Google Patents

Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου

Info

Publication number
CY1112649T1
CY1112649T1 CY20121100086T CY121100086T CY1112649T1 CY 1112649 T1 CY1112649 T1 CY 1112649T1 CY 20121100086 T CY20121100086 T CY 20121100086T CY 121100086 T CY121100086 T CY 121100086T CY 1112649 T1 CY1112649 T1 CY 1112649T1
Authority
CY
Cyprus
Prior art keywords
group
carbazole derivatives
solvates
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
CY20121100086T
Other languages
English (en)
Inventor
Masakazu Murata
Yoshihiko Itokazu
Ryu Nakao
Original Assignee
Zeria Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeria Pharmaceutical Co., Ltd filed Critical Zeria Pharmaceutical Co., Ltd
Publication of CY1112649T1 publication Critical patent/CY1112649T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ένα αντικείμενο της παρούσας εφεύρεσης είναι να παρέχει νέα παράγωγα καρβαζολίου, διαλυτώματα αυτών ή φαρμακευτικώς αποδεκτά άλατα αυτών που έχουν εξαιρετικό αποτέλεσμα μείωσης βάρους λιπώδους ιστού, υπογλυκαιμικό αποτέλεσμα και υπολιπιδαιμικό αποτέλεσμα, που είναι χρήσιμα ως αποτρεπτικός ή/και θεραπευτικός παράγων για λιπαρό ήπαρ, παχυσαρκία, ανωμαλία μεταβολισμού λιπιδίου, σπλαχνική λιπαρότητα, διαβήτη, υπερλιπαιμία, εξασθενημένη ανοχή γλυκόζης, υπέρταση, μη-αλκοολική νόσο λιπαρού ήπατος, μη-αλκοολική στεατοηπατίτιδα και τις παρόμοιες. Το ανωτέρω αναφερθέν αντικείμενο μπορεί να επιτευχθεί με παράγωγα καρβαζολίου, διαλυτώματα αυτών ή φαρμακευτικώς αποδεκτά άλατα αυτών, όπου τα παράγωγα καρβαζολίου αντιπροσωπεύονται από τον ακόλουθο γενικό τύπο (Ι):
CY20121100086T 2004-10-29 2012-01-25 Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου CY1112649T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004316872 2004-10-29
EP05799893A EP1852433B1 (en) 2004-10-29 2005-10-28 Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
CY1112649T1 true CY1112649T1 (el) 2016-02-10

Family

ID=36227999

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100086T CY1112649T1 (el) 2004-10-29 2012-01-25 Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου

Country Status (16)

Country Link
US (1) US8329913B2 (el)
EP (1) EP1852433B1 (el)
JP (1) JP3997491B2 (el)
KR (1) KR101223820B1 (el)
CN (1) CN101048402B (el)
AT (1) ATE534646T1 (el)
AU (1) AU2005297800B2 (el)
CA (1) CA2585642C (el)
CY (1) CY1112649T1 (el)
DK (1) DK1852433T3 (el)
ES (1) ES2378177T3 (el)
PL (1) PL1852433T3 (el)
PT (1) PT1852433E (el)
SI (1) SI1852433T1 (el)
TW (1) TW200635922A (el)
WO (1) WO2006046779A1 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393181B2 (en) 2004-09-17 2008-07-01 The Penn State Research Foundation Expandable impeller pump
WO2007112033A2 (en) 2006-03-23 2007-10-04 The Penn State Research Foundation Heart assist device with expandable impeller pump
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
EP2448613B1 (en) 2009-07-01 2019-11-06 The Penn State Research Foundation Blood pump with expandable cannula
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
ES2676209T3 (es) 2010-06-23 2018-07-17 Metabolex Inc. Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
CN102382037B (zh) * 2010-09-03 2016-01-20 中国医学科学院药物研究所 苯丙酸类化合物及其制法和药物用途
US8485961B2 (en) 2011-01-05 2013-07-16 Thoratec Corporation Impeller housing for percutaneous heart pump
US8597170B2 (en) 2011-01-05 2013-12-03 Thoratec Corporation Catheter pump
WO2012094641A2 (en) 2011-01-06 2012-07-12 Thoratec Corporation Percutaneous heart pump
US8591393B2 (en) 2011-01-06 2013-11-26 Thoratec Corporation Catheter pump
US9327067B2 (en) 2012-05-14 2016-05-03 Thoratec Corporation Impeller for catheter pump
US8721517B2 (en) 2012-05-14 2014-05-13 Thoratec Corporation Impeller for catheter pump
US9872947B2 (en) 2012-05-14 2018-01-23 Tc1 Llc Sheath system for catheter pump
US9446179B2 (en) 2012-05-14 2016-09-20 Thoratec Corporation Distal bearing support
DE102013008168A1 (de) 2012-05-14 2013-11-14 Thoratec Corporation Laufrad für Katheterpumpe
US9358329B2 (en) 2012-07-03 2016-06-07 Thoratec Corporation Catheter pump
EP4186557A1 (en) 2012-07-03 2023-05-31 Tc1 Llc Motor assembly for catheter pump
US9421311B2 (en) 2012-07-03 2016-08-23 Thoratec Corporation Motor assembly for catheter pump
US11077294B2 (en) 2013-03-13 2021-08-03 Tc1 Llc Sheath assembly for catheter pump
EP4122520A1 (en) 2013-03-13 2023-01-25 Tc1 Llc Fluid handling system
US11033728B2 (en) 2013-03-13 2021-06-15 Tc1 Llc Fluid handling system
EP3797810A1 (en) 2013-03-15 2021-03-31 Tc1 Llc Catheter pump assembly including a stator
US9308302B2 (en) 2013-03-15 2016-04-12 Thoratec Corporation Catheter pump assembly including a stator
EP3131599B1 (en) 2014-04-15 2019-02-20 Tc1 Llc Catheter pump with access ports
EP3131597B1 (en) 2014-04-15 2020-12-02 Tc1 Llc Catheter pump introducer systems
US10029037B2 (en) 2014-04-15 2018-07-24 Tc1 Llc Sensors for catheter pumps
WO2015160942A1 (en) 2014-04-15 2015-10-22 Thoratec Corporation Catheter pump with off-set motor position
WO2016028644A1 (en) 2014-08-18 2016-02-25 Thoratec Corporation Guide features for percutaneous catheter pump
EP3598986B1 (en) 2015-01-22 2021-02-17 Tc1 Llc Motor assembly with heat exchanger for catheter pump
WO2016118784A1 (en) 2015-01-22 2016-07-28 Thoratec Corporation Attachment mechanisms for motor of catheter pump
US9770543B2 (en) 2015-01-22 2017-09-26 Tc1 Llc Reduced rotational mass motor assembly for catheter pump
US9907890B2 (en) 2015-04-16 2018-03-06 Tc1 Llc Catheter pump with positioning brace
US11160970B2 (en) 2016-07-21 2021-11-02 Tc1 Llc Fluid seals for catheter pump motor assembly
US11491322B2 (en) 2016-07-21 2022-11-08 Tc1 Llc Gas-filled chamber for catheter pump motor assembly
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2019071216A1 (en) 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003377A1 (en) 1994-07-27 1996-02-08 Sankyo Company, Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
BR9713261A (pt) 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
MY125942A (en) * 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
WO2001026653A1 (fr) 1999-10-15 2001-04-19 Shionogi & Co., Ltd. Inhibiteurs spla2 du type v et/ou du type x
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000257A1 (fr) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes a la maladie d'alzheimer
EP1300159B1 (en) 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedies for cancer
TWI314457B (el) 2001-03-19 2009-09-11 Shionogi & Co
JP2004525154A (ja) 2001-03-28 2004-08-19 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしての置換カルバゾール
WO2004024939A2 (en) 2002-09-13 2004-03-25 Georgetown University Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity

Also Published As

Publication number Publication date
CA2585642C (en) 2013-04-02
ES2378177T3 (es) 2012-04-09
ATE534646T1 (de) 2011-12-15
PT1852433E (pt) 2012-02-08
TW200635922A (en) 2006-10-16
KR20070072554A (ko) 2007-07-04
AU2005297800A1 (en) 2006-05-04
CA2585642A1 (en) 2006-05-04
SI1852433T1 (sl) 2012-06-29
EP1852433A1 (en) 2007-11-07
CN101048402A (zh) 2007-10-03
TWI359148B (el) 2012-03-01
DK1852433T3 (da) 2012-01-30
EP1852433B1 (en) 2011-11-23
EP1852433A4 (en) 2010-07-21
JP3997491B2 (ja) 2007-10-24
PL1852433T3 (pl) 2012-05-31
JPWO2006046779A1 (ja) 2008-05-22
KR101223820B1 (ko) 2013-01-17
WO2006046779A1 (ja) 2006-05-04
US20100286210A1 (en) 2010-11-11
AU2005297800B2 (en) 2011-02-03
US8329913B2 (en) 2012-12-11
CN101048402B (zh) 2011-11-09

Similar Documents

Publication Publication Date Title
CY1112649T1 (el) Παραγωγο καρβαζολιου, διαλυτωμα αυτου ή φαρμακευτικως αποδεκτο αλας αυτου
AP804A (en) APO-B-secretion/MTP inhibitory amides.
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
EP3091020A3 (en) Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
ATE530066T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
WO2004089918A1 (ja) 複素芳香５員環化合物及びその医薬用途
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
WO2009123164A1 (ja) 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
JP2007126454A (ja) アニリド誘導体
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
MX2007006504A (es) Derivados de malonamida como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer.
UA89067C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
WO2008062830A1 (fr) Composé de spiroquinone et composition pharmaceutique
JP4832897B2 (ja) エステル誘導体及びその医薬用途
ZA200805740B (en) Novel polyunsaturated compounds, method for preparing same and compositions containing same
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
TR201808812T4 (tr) Fenil derivesi.
EP2226321A3 (en) Process for producing thiazolidinediones and intermediates thereof
JP2009001496A (ja) ２−チエニルウレア誘導体
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents
WO2001096309A1 (fr) Derives hydroxyformamidine et medicaments les contenant
TW200626143A (en) Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy
RU2009123645A (ru) Способы повышения биодоступности ингибитора ренина